Sunday, November 16, 2008 2:39:35 PM
HIV/AIDS Testing Market to Exceed $3.9 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
Revolutionary developments in the field of HIV disease monitoring and management have had its direct impact on HIV testing market. The report forecasts worldwide HIV/AIDS Testing market to exceed $3.9 billion by 2015.
San Jose, California (PRWEB) October 23, 2008 -- Earlier considered a life threatening disease, HIV/AIDS has now emerged as a persistent condition that necessitates efficient disease management. Such a change has encouraged people to increasingly adopt HIV testing procedures, though the trend is pronounced in developed countries, and is gaining momentum in developing nations. Revolutionary changes in HIV disease monitoring and management have had a significant influence on the HIV testing market. New disease-progression study techniques such as genotyping and phenotyping, and advancements in viral load monitoring tests have significantly improved therapies offered to HIV/AIDS infected individuals.
United States and Europe together accounted for over 60% share of the worldwide HIV/AIDS Testing market in 2008, as stated in a recent report published by Global Industry Analysts, Inc. The relatively saturated markets in developed regions of the world are expected to be driven by enhanced emphasis on reducing infection rates. Asia-Pacific is projected to witness the fastest growth over the analysis period. Africa, China, and India accounting for about 90% of world HIV population, offer enormous potential for makers of HIV/AIDS Testing products. HIV/AIDS Screening Tests market is projected to generate US$1.3 billion revenues by the year 2010. Growth in the monitoring market is highly dependent on success of HIV therapies. Development of new products is likely to bring about further fragmentation of the market. HIV/AIDS Monitoring Test market is projected to reach US$1.7 billion by 2015. The market is particularly driven by the rising instances of drug resistance and increasing number of genotyping tests. US and Europe account for about 75% of the market size. This is partly due to affordability and accessibility of these expensive tests in the regions.
HIV/AIDS Testing: A Global Strategic Business Report
United States HIV/AIDS Testing market is one of the highly developed and regulated markets in the world. HIV/AIDS confirmatory tests market in the region is projected to reach US$32 million by 2015. With disease management taking precedence, new product introductions are likely to become the mainstay of many companies. Developments in monitoring markets along with HIV therapies, and development of molecular testing and probe technologies in Europe, are likely to have the highest positive impact in HIV testing market in the long run. In Europe, France, Germany, Italy, and the United Kingdom command more than 65% of the European market.
Rapid test kits are likely to attract large customers as they claim to offer instant results. Several producers are focused on developing rapid HIV test kit that produce results in less time and are solely aimed at diagnosis. When compared with the popular enzyme-linked immunosorbent assay (ELISA) testing kits present in the market, rapid test kits take much lesser time to detect, do not require any specialized equipment and are also less complicated. A key trend noticed in the rapid testing market is combined HIV testing built on multiple sampling modalities.
Blood Screening has emerged as a growing market for nucleic acid based tests. This is mainly attributable to mandatory testing for blood donations initiated by countries such as the United States for HIV-1 and HCV.
Key players in world HIV/AIDS testing market with significant presence include Abbott Laboratories Inc., Adaltis Inc., Siemens Healthcare Diagnostics Inc., Biomérieux SA, Bio-Rad Laboratories Inc., Calypte Biomedical Corporation, Celera Group, Gen-Probe Inc., Innogenetics NV, MedMira Laboratories, Inc., Medical Services International Inc., OraSure Technologies Inc., Ortho-Clinical Diagnostics Inc., and Roche Diagnostics. In the rapid testing market, key participants comprise Orasure, Trinity Biotech, Calypte Biomedical Corporation, Medical Services International Inc., and MedMira. OraSure Technologies, Inc. leads the market for oral fluid diagnostics worldwide.
The report titled "HIV/AIDS Testing: A Global Strategic Business Report" published by Global Industry Analysts, Inc., covers major market dynamics, trends, issues, and competition pertaining to the market on a global as well as regional level. The report enumerates recent product innovations and launches, developments, mergers, acquisitions and other strategic industry activities. Analysis is presented for established and emerging markets including United States, Japan, France, Germany, United Kingdom, Italy, Spain, Asia-Pacific, Latin America, and rest of World. The report focuses on various regional statistics and growth drivers including development of rapid HIV test kits, rising awareness amongst the general population, and measures undertaken to reduce rate of HIV infection. The study examines the regulatory environment governing HIV/AIDS testing market across the world. The report analyzes volume sales across two principal product segments, namely HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests. Revenues are analyzed across three segments, namely HIV/AIDS Screening Tests, HIV/AIDS Confirmatory Tests, and HIV/AIDS Monitoring Tests. Analytics are provided for the period 2000-2015.
For more details of this research report, please visit http://www.strategyr.com/HIV_AIDS_Testing_Market_Report.asp
About Global Industry Analysts, Inc.
Global Industry Analysts, Inc., (GIA) is a reputed publisher of off-the-shelf market research. Founded in 1987, the company is globally recognized as one of the world's largest market research publishers. The company employs over 700 people worldwide and publishes more than 880 full-scale research reports each year. Additionally, the company also offers a range of over 60,000 smaller research products including company reports, market trend reports, and industry reports encompassing all major industries worldwide.
Global Industry Analysts, Inc.
Telephone 408-528-9966
Fax 408-528-9977
Email press@StrategyR.com
Web Site http://www.strategyr.com/
Recent TRIB News
- Trinity Biotech to Begin European Pre-Pivotal Trial to Optimize its CGM Sensor • GlobeNewswire Inc. • 06/24/2024 11:00:00 AM
- Trinity Biotech Attending 84th Scientific Sessions of the American Diabetes Association • GlobeNewswire Inc. • 06/10/2024 01:10:36 PM
- Trinity Biotech Launches its Continuous Glucose Monitoring Microsite to Showcase its Innovative & Differentiated Technology • GlobeNewswire Inc. • 06/03/2024 08:00:00 AM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/28/2024 11:55:23 AM
- Trinity Biotech Announces Q1 2024 Financial Results and Reiterates Guidance • GlobeNewswire Inc. • 05/23/2024 12:00:32 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 05/16/2024 05:15:37 PM
- Trinity Biotech Announces Strategic Collaboration with Medical Artificial Intelligence Company PulseAI • GlobeNewswire Inc. • 05/16/2024 01:18:57 PM
- Trinity Biotech Announces Increased Orders for TrinScreen HIV and Raises Guidance for 2024 TrinScreen HIV Sales • GlobeNewswire Inc. • 05/13/2024 03:42:27 PM
- Trinity Biotech Welcomes Avinash Kale as Continuous Glucose Monitor Programme Director to Advance Innovation and Development • GlobeNewswire Inc. • 05/08/2024 02:36:58 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 05/08/2024 04:15:26 AM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 05/07/2024 08:25:53 PM
- Trinity Biotech Announces Fourth Quarter and Fiscal Year 2023 Financial Results & Business Updates • GlobeNewswire Inc. • 04/04/2024 11:30:02 AM
- Trinity Biotech plc to Announce Q4 and Fiscal Year 2023 Financial Results • GlobeNewswire Inc. • 03/28/2024 10:39:07 PM
- Trinity Biotech Regains Compliance with Nasdaq Minimum Closing Bid Price Rule • GlobeNewswire Inc. • 03/08/2024 03:03:48 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 02/15/2024 07:11:36 PM
- Trinity Biotech Plc Finalizes Effective Date of ADS Ratio Change • GlobeNewswire Inc. • 02/15/2024 05:34:50 PM
- Trinity Biotech Plc Announces Plan to Implement ADS Ratio Change • GlobeNewswire Inc. • 02/13/2024 02:00:12 PM
- Form SC 13D - General statement of acquisition of beneficial ownership • Edgar (US Regulatory) • 02/10/2024 12:51:28 AM
- Trinity Biotech to Present at Emerging Growth Conference • GlobeNewswire Inc. • 02/08/2024 01:30:00 PM
- Trinity Biotech Announces Application for Early Sjogrens Syndrome Test Panel PLA Code • GlobeNewswire Inc. • 02/07/2024 01:30:00 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:37:17 PM
- Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16] • Edgar (US Regulatory) • 02/01/2024 04:33:32 PM
- Trinity Biotech Announces Q3 2023 Financial Results & Business Update • GlobeNewswire Inc. • 01/31/2024 12:05:00 PM
- Trinity Biotech Announces Entry into a Letter of Intent with Bayer for a Joint Partnership to Launch a CGM Biosensor Device in China and India • GlobeNewswire Inc. • 01/31/2024 12:02:00 PM
- Trinity Biotech Announces Acquisition of the CGM Assets of Waveform Technologies, Inc. • GlobeNewswire Inc. • 01/31/2024 12:00:00 PM
VAYK Exited Caribbean Investments for $320,000 Profit • VAYK • Jun 27, 2024 9:00 AM
North Bay Resources Announces Successful Flotation Cell Test at Bishop Gold Mill, Inyo County, California • NBRI • Jun 27, 2024 9:00 AM
Branded Legacy, Inc. and Hemp Emu Announce Strategic Partnership to Enhance CBD Product Manufacturing • BLEG • Jun 27, 2024 8:30 AM
POET Wins "Best Optical AI Solution" in 2024 AI Breakthrough Awards Program • POET • Jun 26, 2024 10:09 AM
HealthLynked Promotes Bill Crupi to Chief Operating Officer • HLYK • Jun 26, 2024 8:00 AM
Bantec's Howco Short Term Department of Defense Contract Wins Will Exceed $1,100,000 for the current Quarter • BANT • Jun 25, 2024 10:00 AM